Cargando…

Treatments for COVID-19: emerging drugs against the coronavirus - reply

Detalles Bibliográficos
Autor principal:	Potì, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2020
Materias:	Correspondence / Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716991/ https://www.ncbi.nlm.nih.gov/pubmed/32921741 http://dx.doi.org/10.23750/abm.v91i3.10108

Ejemplares similares

Treatments for COVID-19: emerging drugs against the coronavirus
por: Khademolhosseini, Sara, et al.
Publicado: (2020)

Treatments for COVID-19: emerging drugs against the coronavirus
por: Potì, Francesco, et al.
Publicado: (2020)

COVID-19… What are drugs and strategies now?
por: Bellini, Valentina, et al.
Publicado: (2021)

In Reply: Neurosurgery and Coronavirus (COVID-19) Epidemic: Doing Our Part
por: Tomasi, S Ottavio, et al.
Publicado: (2020)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

In reply: Uncertainty in using chest computed tomography in early coronavirus disease (COVID-19)
por: Chen, Rong, et al.
Publicado: (2020)

Timing and sequence of vaccination against COVID-19 and influenza – Author's reply
por: Dulfer, Elisabeth A., et al.
Publicado: (2023)

Prone Positioning in COVID-19 ARDS: Reply
por: Zarantonello, Francesco, et al.
Publicado: (2023)

Reply: Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19
por: Havaki, Sophia, et al.
Publicado: (2022)

Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
por: Murakami, Naoka, et al.
Publicado: (2023)

Management of diabetes in patients with COVID-19 – Authors' reply
por: Bornstein, Stefan R, et al.
Publicado: (2020)

Reply to: COVID-19 and Coagulopathy
por: Rodríguez, Cristina, et al.
Publicado: (2021)

Inhaled budesonide for early treatment of COVID-19 – Authors' reply
por: Ramakrishnan, Sanjay, et al.
Publicado: (2021)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Reply to: Neuroimmune interactions and COVID-19 in lung transplant recipients
por: De Virgiliis, Francesco, et al.
Publicado: (2021)

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design
por: Porcher, Raphaël, et al.
Publicado: (2022)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”
por: Nicolini, Laura Ambra, et al.
Publicado: (2020)

COVID-19 Vasculopathy and Post–COVID-19 Phenomenon: Reply
por: Akgul, Ahmet
Publicado: (2021)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Reply: COVID-19, A and Hypersensitivity Pneumonitis
por: Shin, Hyoung-Shik
Publicado: (2020)

Reply to Epelbaum: Standards and Stereotypes in COVID-19
por: Ziehr, David R., et al.
Publicado: (2020)

In Reply to ‘COVID-19–Associated Kidney Injury’
por: Patel, Niralee, et al.
Publicado: (2020)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

On Ventricular Aneurysms, Thrombi, and COVID-19: Reply
por: Hui, Dawn S., et al.
Publicado: (2021)

Surgical Training in the Era of COVID-19: Reply
por: Fuller, Stephanie
Publicado: (2021)

COVID-19 and preterm birth – Authors' reply
por: Choudhary, Rahul, et al.
Publicado: (2021)

Neuropsychiatric disorders and COVID-19 – Authors' reply
por: Taquet, Maxime, et al.
Publicado: (2021)

COVID-19 and myocardial infarction – Authors' reply
por: Katsoularis, Ioannis, et al.
Publicado: (2021)

COVID-19 research in LMICs – Authors' reply
por: Torres, Irene, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs
por: Georgiev, Tsvetoslav
Publicado: (2020)

Reply: Introducing special cutaneous “sign” tribute to health care workers managing new coronavirus disease 2019 (COVID-19)
por: Darlenski, Razvigor, et al.
Publicado: (2020)

Bariatric and metabolic surgery during and after the COVID-19 pandemic – Authors' reply
por: Cummings, David E, et al.
Publicado: (2020)

Reply: Aseptic Meningitis and mRNA Coronavirus Disease 2019 Vaccine
por: Heo, Sang Taek
Publicado: (2022)

Frailty and mortality in patients with COVID-19 – Authors' reply
por: McCarthy, Kathryn, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Reply to: Ivermectin in COVID-19. Argumentum ad ignorantiam?()
por: López Reboiro, M.L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7mgahc0mfftf7aksd2ufj0t5qn